Company intelligence / Profile preview

AlliedCel Corporation

Kobe, Hyogo, Japan

Ownership: Private
Development stage: Other

Overview

Early-stage joint venture focused on R&D, manufacturing, and commercialization of regenerative medicine products using stem cells and other cells; licensed JB-101 for immune tolerance induction in transplantation.

Therapeutic areas: Immunology
Modalities: Cell therapyStem cell therapy
Industry: Biotech

Partnerships

Sysmex CorporationJCR Pharmaceuticals Co., Ltd.JUNTEN BIO Co., Ltd.

Beyond the preview

Go deeper on AlliedCel Corporation.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on AlliedCel Corporation.

Explore the full profile